KINE 501D
Alternative Names: KINE-501DLatest Information Update: 11 Mar 2024
At a glance
- Originator Kine Sciences
- Class Antiparkinsonians; Peptides
- Mechanism of Action Alpha-synuclein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 06 Feb 2024 Early research in Parkinson's disease in South Korea (unspecified route) prior to February 2024 (Kine Sciences pipeline, February 2024)